seri
novel
substitut
synthes
target
compound
evalu
anticanc
activ
vitro
within
dtp
nci
protocol
among
test
compound
deriv
found
activ
demonstr
certain
sensit
profil
toward
leukemia
subpanel
cell
line
gi
valu
rang
mm
mm
screen
antitrypanosom
antivir
activ
carri
promis
influenc
mention
compound
trypanosoma
brucei
minim
effect
sar
coronaviru
influenza
type
b
virus
noncondens
heterocycl
system
thiazolidinon
pyrazolin
moieti
emerg
power
scaffold
drug
design
among
diazolesubstitut
highli
activ
anticanc
agent
identifi
includ
inhibitor
necroptosi
tumor
necrosi
factor
tyrosin
phosphatas
previou
studi
base
hybrid
pharmacophor
approach
allow
establish
number
pattern
structureeact
relationship
sar
context
pyrazolin
fragment
posit
thiazolidon
cycl
possess
antitumor
activ
hand
thiazolidinon
pyrazolin
occupi
uniqu
posit
design
synthesi
novel
biolog
activ
agent
exert
trypanocid
activ
acid
deriv
identifi
inhibitor
trypanosoma
brucei
dolicholphosph
mannos
synthas
acid
deriv
shown
promis
activ
cruzipain
proteas
promis
compound
seri
shown
activ
noncytotox
concentr
vitro
assay
trypanosoma
cruzi
cell
cultur
exhibit
potenc
compar
refer
compound
ic
strain
mm
among
pyrazolin
deriv
novel
compound
identifi
inhibitor
trypanosom
cystein
proteas
cruzain
ic
nm
antivir
activ
heteryl
substitut
promis
among
thiazoleethiazolidin
conjug
noncondens
deriv
thiazolidinon
pyridin
pyrimidin
cycl
antihiv
agent
identifi
addit
group
compound
activ
hepat
c
viru
tobacco
mosaic
viru
vesicular
stomat
viru
previous
also
demonstr
effici
certain
pyrazolineethiazolidinon
conjug
influenza
virus
sar
coronaviru
present
work
extens
ongo
effort
toward
develop
promis
biolog
activ
agent
use
hybrid
pharmacophor
approach
made
design
fig
synthes
hybrid
compound
link
main
structur
unit
ring
system
pyrazolin
examin
antitumor
trypanocid
antivir
activ
vitro
found
two
compound
substitut
possess
commensur
antitumor
activ
compar
pyrazolineethiazolidinon
analog
compound
report
previous
evalu
antitrypanosom
activ
antivir
activ
synthes
compound
gener
method
synthesi
target
thiazolidinone
pyrazolin
conjug
depict
scheme
start
synthes
use
known
method
appropri
chalcon
easili
react
yield
known
chemic
modif
posit
thiazolidinon
cycl
essenti
influenc
antitumor
activ
reli
observ
util
potassium
salt
gener
situ
reaction
follow
mention
reaction
new
noncondens
thiazolidinoneepyrazolin
conjug
synthes
base
mannich
reaction
secondari
amin
thiazolidinon
analog
obtain
scheme
aim
detail
elabor
sar
especi
influenc
link
group
thiazolidinoneepyrazolin
conjug
anticanc
activ
synthes
method
describ
previous
reaction
acetyl
chlorid
afford
excel
yield
puriti
compound
follow
reaction
gener
situ
potassium
salt
group
synthes
scheme
data
character
synthes
novel
heterocycl
substitut
thiazolidon
present
experiment
part
analyt
spectral
data
h
nmr
c
nmr
confirm
structur
synthes
compound
proton
ch
ech
pyrazolin
fragment
h
nmr
spectra
synthes
compound
show
characterist
pattern
amx
system
proton
ch
thiazolidinon
core
show
broad
singlet
proton
methylen
group
ch
co
appear
broad
singlet
ppm
h
nmr
spectra
nh
proton
thiazolidinon
cycl
broad
singlet
found
synthes
deriv
select
nation
cancer
institut
nci
bethesda
usa
development
therapeut
program
dtp
evalu
concentr
toward
panel
approxim
sixti
cancer
cell
line
http
dtpncinihgov
human
tumor
cell
line
deriv
nine
differ
cancer
type
leukemia
melanoma
lung
colon
central
nervou
system
ovarian
renal
prostat
breast
cancer
primari
anticanc
assay
perform
accord
nci
protocol
describ
elsewher
compound
ad
singl
concentr
cell
cultur
incub
h
end
point
determin
made
protein
bind
dye
sulforhodamin
b
srb
result
compound
report
percent
growth
gp
treat
cell
compar
untreat
control
cell
tabl
rang
percent
growth
show
lowest
highest
percent
growth
found
among
differ
cancer
cell
line
activ
compound
found
effect
cell
line
respect
compound
found
moder
effect
cell
line
compound
show
activ
tabl
final
compound
select
advanc
assay
panel
approxim
sixti
tumor
cell
line
dilut
five
concentr
mm
mm
mm
mm
mm
percentag
growth
evalu
spectrophotometr
versu
control
treat
test
agent
exposur
use
srb
protein
assay
estim
cell
viabil
growth
doseerespons
paramet
calcul
cell
line
gi
e
molar
concentr
compound
inhibit
net
cell
growth
tgi
e
molar
concentr
compound
lead
total
inhibit
furthermor
mean
graph
midpoint
mgmid
calcul
paramet
give
averag
activ
paramet
cell
line
test
compound
mgmid
calcul
insensit
cell
line
includ
highest
concentr
test
tabl
test
compound
show
inhibit
activ
gi
mm
human
tumor
cell
averag
gi
tgi
valu
mm
mm
mm
tabl
regard
sensit
individu
cell
line
among
sever
subpanel
compound
demonstr
certain
sensit
profil
toward
leukemia
subpanel
tumor
cell
line
gi
valu
rang
mm
mm
tabl
sar
studi
reveal
level
antitumor
activ
activ
thiazolidinon
pyrazolin
fragment
posit
compat
effect
level
heteryl
substitut
thiazolidon
describ
previous
conjug
pyrazolin
thiazolidinon
cycl
use
oxomethyliden
link
group
allow
us
increas
activ
comparison
structur
relat
conjug
repres
introduct
substitu
thiazolidin
fragment
signific
influenc
antitumor
activ
nci
compar
algorithm
allow
assum
biochem
mechan
action
novel
compound
basi
vitro
activ
profil
compar
standard
agent
perform
compar
comput
compound
nci
standard
agent
databas
gi
tgi
level
tabl
howev
obtain
pearson
correl
coeffici
pcc
allow
distinguish
cytotox
mechan
test
compound
high
probabl
compound
show
highest
correl
gi
level
dihydroorot
dehydrogenas
inhibitor
brequinar
pcc
compound
e
maytansin
rnadna
antimetabolit
pcc
antivir
activ
determin
sar
coronaviru
sar
cov
influenza
type
b
virus
flu
flu
b
obtain
result
summar
tabl
although
antivir
activ
evid
viru
inhibit
occur
near
cytotox
concentr
compound
show
insignific
activ
four
strain
influenza
viru
rang
level
select
index
compound
moder
activ
duck
strain
influenza
effect
concentr
ec
mm
select
index
si
signific
activ
influenza
strain
major
compound
show
activ
sar
cov
posit
control
compound
ribavirin
oseltamivir
carboxyl
activ
expect
assay
compound
select
advanc
vitro
assay
trypanosoma
brucei
brucei
tbb
trypanosoma
brucei
gambiens
tbg
doseerespons
curv
drug
concentr
rang
mgml
mgml
depict
result
show
moder
activ
compound
tabl
parasit
strain
name
ic
tbb
mm
ic
tbg
mm
present
paper
new
base
conjug
pyrazolin
moieti
posit
describ
antitumor
activ
assay
thirteen
synthes
compound
allow
us
identifi
highli
activ
thiazolidinoneepyrazolin
hybrid
demonstr
certain
sensit
profil
toward
leukemia
subpanel
tumor
cell
line
gi
valu
rang
mm
start
acetyl
chlorid
obtain
accord
tabl
anticanc
screen
data
concentr
mm
method
describ
previous
prepar
compound
describ
previou
report
suspens
compound
mmol
potassium
hydroxid
mmol
stir
rt
min
later
appropri
mmol
ad
mixtur
reflux
h
etoh
ml
obtain
powder
filter
wash
ethanol
recrystal
dmf
ethanol
mixtur
yield
mp
c
antitrypanosom
activ
deriv
solut
acetyl
chlorid
mmol
ml
dioxan
ad
mixtur
appropri
mmol
triethylamin
mmol
ml
dioxan
later
heat
c
min
cool
pour
water
ml
obtain
powder
filter
wash
water
recrystal
dmf
ethanol
mixtur
result
test
compound
report
percent
growth
treat
cell
compar
untreat
control
cell
percentag
growth
evalu
spectrophotometr
versu
control
treat
test
agent
cytotox
andor
growth
inhibitori
effect
activ
select
compound
test
vitro
full
panel
human
tumor
cell
line
concentr
rang
continu
drug
exposur
protocol
follow
srb
protein
assay
use
estim
cell
viabil
growth
use
absorb
measur
time
zero
tz
control
growth
absenc
drug
c
test
growth
presenc
drug
ti
percentag
growth
calcul
drug
concentr
percentag
growth
inhibit
calcul
concentr
ti
tz
concentr
ti
tz
dose
respons
paramet
gi
tgi
calcul
compound
growth
inhibit
gi
calcul
ti
tz
c
tz
drug
concentr
result
lower
net
protein
increas
treat
cell
measur
srb
stain
compar
net
protein
increas
seen
control
cell
drug
concentr
result
total
growth
inhibit
tgi
calcul
ti
tz
valu
calcul
paramet
level
activ
reach
howev
effect
reach
excess
valu
paramet
express
less
maximum
minimum
concentr
test
lowest
valu
obtain
sensit
cell
line
compound
gi
valu
mm
declar
activ
primari
antivir
assay
perform
respiratori
virus
panel
flu
flu
flu
flu
b
sar
cov
compound
dilut
mgml
dmso
eight
halflog
dilut
prepar
mem
solut
mgml
gentamicin
dilut
ad
well
plate
confluent
cell
three
well
dilut
infect
test
viru
use
multipl
infect
per
cell
viru
two
well
remain
uninfect
toxic
control
known
activ
compound
run
parallel
control
cytopath
effect
cpe
observ
microscop
plate
stain
neutral
red
dye
approxim
h
supernat
dye
remov
well
incorpor
dye
extract
sorensen
citrat
bufferethanol
read
spectrophotomet
nm
optic
densiti
test
well
convert
percent
cell
viru
control
concentr
test
compound
requir
inhibit
viral
cpe
ec
calcul
regress
analysi
concentr
compound
would
caus
cytotox
uninfect
cell
similarli
calcul
cc
ec
cc
present
mm
select
index
si
cc
divid
ec
bloodstream
form
brucei
brucei
strain
brucei
gambiens
feo
strain
cultur
medium
supplement
fc
c
atmospher
co
experi
logphas
parasit
cultur
harvest
centrifug
immedi
use
drug
assay
base
convers
redoxsensit
dye
resazurin
fluoresc
product
viabl
cell
previous
describ
drug
stock
solut
prepar
pure
dmso
brucei
bloodstream
form
cellsml
cultur
plate
either
absenc
presenc
differ
concentr
inhibitor
final
volum
ml
incub
resazurin
solut
ad
well
final
concentr
mm
fluoresc
measur
nm
nm
absorb
incub
percentag
inhibit
parasit
growth
rate
calcul
compar
fluoresc
parasit
maintain
presenc
drug
absenc
drug
dmso
use
control
concentr
inhibit
parasit
growth
ic
determin
doseerespons
curv
drug
concentr
rang
mgml
mgml
present
mm
ic
valu
mean
standard
deviat
three
independ
experi
